These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20923712)

  • 21. Long-term citicoline (cytidine diphosphate choline) use in patients with vascular dementia: neuroimaging and neuropsychological outcomes.
    Cohen RA; Browndyke JN; Moser DJ; Paul RH; Gordon N; Sweet L
    Cerebrovasc Dis; 2003; 16(3):199-204. PubMed ID: 12865605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment and prevention of cognitive dysfunction in patients with arterial hypertension and atherosclerosis: results of a randomized double-blind placebo-controlled trial of cerebrolysin].
    Vereshchagin NV; Suslina ZA; Timerbaeva SL; Kashina EM; Gnezditskiĭ VV; Maksimova MIu; Rebrova OIu; Smirnova IN
    Ter Arkh; 2001; 73(4):22-7. PubMed ID: 11494441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study.
    Weyer G; Eul A; Milde K; Wierich W; Herrmann WM
    Pharmacopsychiatry; 2000 May; 33(3):89-97. PubMed ID: 10855459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects.
    Alvarez XA; Lombardi VR; Corzo L; Pérez P; Pichel V; Laredo M; Hernández A; Freixeiro F; Sampedro C; Lorenzo R; Alcaraz M; Windisch M; Cacabelos R
    J Neural Transm Suppl; 2000; 59():315-28. PubMed ID: 10961443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles.
    Le Bars PL
    Pharmacopsychiatry; 2003 Jun; 36 Suppl 1():S50-5. PubMed ID: 13130389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cerebrolysin treatment of mild cognitive impairment of vascular genesis].
    Damulin IV; Mkhitarian EA; Koberskaia NN
    Ter Arkh; 2007; 79(6):65-9. PubMed ID: 17684971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrolysin: a review of its use in dementia.
    Plosker GL; Gauthier S
    Drugs Aging; 2009; 26(11):893-915. PubMed ID: 19848437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
    Mecocci P; Bladström A; Stender K
    Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy of prolonged therapy of vascular dementia].
    Klin Med (Mosk); 2011; 89(5):57-60. PubMed ID: 22242270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained improvement of cognition and global function in patients with moderately severe Alzheimer's disease: a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin.
    Ruether E; Alvarez XA; Rainer M; Moessler H
    J Neural Transm Suppl; 2002; (62):265-75. PubMed ID: 12456069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroimaging correlates of dementia rating scale performance at baseline and 12-month follow-up among patients with vascular dementia.
    Sweet LH; Paul RH; Cohen RA; Moser D; Ott BR; Gordon N; Browndyke JN; Shah P; Garrett KD
    J Geriatr Psychiatry Neurol; 2003 Dec; 16(4):240-4. PubMed ID: 14653434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia.
    Allegri RF; Guekht A
    Drugs Today (Barc); 2012 Apr; 48 Suppl A():25-41. PubMed ID: 22514793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [An experimental, randomized, double-blind, placebo-controlled clinical trial to infestigate the effect of nicardipine on cognitive function in patients with vascular dementia. Spanish group of nicardipine study in vascular dementia].
    Rev Neurol; 1999 May 1-15; 28(9):835-45. PubMed ID: 10390744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of cerebrolysin on moderate cognitive impairments in cerebral vascular insufficiency (a clinical-electrophysiological study).
    Damulin IV; Koberskaya NN; Mkhitaryan EA
    Neurosci Behav Physiol; 2008 Jul; 38(6):639-45. PubMed ID: 18607744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic results with Cerebrolysin in the treatment of dementia.
    Rainer M; Brunnbauer M; Dunky A; Ender F; Goldsteiner H; Holl O; Kotlan P; Paulitsch G; Reiner C; Stössl J; Zachhuber C; Mössler H
    Wien Med Wochenschr; 1997; 147(18):426-31. PubMed ID: 9408984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacological approaches to the therapy of Alzheimer's disease].
    Gavrilova SI
    Vestn Ross Akad Med Nauk; 2006; (9-10):30-4. PubMed ID: 17111921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient populations in clinical studies of donepezil in vascular dementia.
    Pratt RD
    Int Psychogeriatr; 2003; 15 Suppl 1():195-200. PubMed ID: 16191240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy.
    Rüther E; Ritter R; Apecechea M; Freytag S; Gmeinbauer R; Windisch M
    J Neural Transm (Vienna); 2000; 107(7):815-29. PubMed ID: 11005546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. P300 auditory event-related potentials and neuropsychological study during donepezil treatment in vascular dementia.
    Paci C; Gobbato R; Carboni T; Sanguigni S; Santone A; Curatola L
    Neurol Sci; 2006 Feb; 26(6):435-7. PubMed ID: 16601937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.